Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Samsung Building $730 Million Biologics CMO Facility in Korea

publication date: Dec 24, 2015
Samsung BioLogics of South Korea began construction this week of a $730 million biologics drug production facility in the Incheon Free Economic Zone, Korea. The new plant is the company's third biologics facility, with a capacity of 180,000 liters. Together with Samsung's two existing facilities, the company will have a total capacity of 360,000 liters, which Samsung says would be the largest capacity for any biologics CMO in the world. All of Samsung's plants are compatible with western standards. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital